Laurence Albiges1, Tom Powles2, Michael Staehler3, Karim Bensalah4, Rachel H Giles5, Milan Hora6, Markus A Kuczyk7, Thomas B Lam8, Börje Ljungberg9, Lorenzo Marconi10, Axel S Merseburger11, Alessandro Volpe12, Yasmin Abu-Ghanem13, Saeed Dabestani14, Sergio Fernández-Pello15, Fabian Hofmann16, Teele Kuusk17, Rana Tahbaz18, Axel Bex19. 1. Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France. 2. The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK. 3. Department of Urology, Ludwig-Maximilians University, Munich, Germany. 4. Department of Urology, University of Rennes, Rennes, France. 5. Patient Advocate, International Kidney Cancer Coalition (IKCC), Duivendrecht, The Netherlands; Department of Nephrology and Hypertension, Regenerative Medicine Center, University Medical Centre Utrecht, Utrecht, The Netherlands. 6. Department of Urology, University Hospital Plzeň, Plzeň, Czech Republic; Faculty of Medicine in Plzeň, Charles University, Plzeň, Czech Republic. 7. Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany. 8. Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK; Academic Urology Unit, University of Aberdeen, Aberdeen, UK. 9. Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden. 10. Department of Urology, Coimbra University Hospital, Coimbra, Portugal. 11. Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany. 12. Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy. 13. Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel. 14. Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Malmö, Sweden. 15. Department of Urology, Cabueñes Hospital, Gijón, Spain. 16. Department of Urology, Sunderby Hospital, Sunderby, Sweden. 17. Department of Urology, Royal Free Hospital, Pond Street, London, UK. 18. Department of Urology, Elbe Kliniken Stade, Stade, Germany. 19. Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, London, UK. Electronic address: a.bex@nki.nl.
Abstract
Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. PATIENT SUMMARY: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.
Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. PATIENT SUMMARY:Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.
Authors: Luciana de M Leite; Paulo G Bergerot; Aldo L A Dettino; José Augusto R; Stenio de C Zequi; Maria Nirvana da C Formiga Journal: Int Braz J Urol Date: 2021 May-Jun Impact factor: 1.541
Authors: Andreas Varkaris; Wenxin Xu; Roger B Davis; Brian Healy; David F McDermott Journal: Clin Genitourin Cancer Date: 2019-12-05 Impact factor: 2.872